BCL2L1 and Miyoshi myopathy: Combined BCL-XL and MCL-1 inhibition, using sub-therapeutic concentrations of BH3 mimetics, potently sensitized MM cells to CFZ-mediated cytotoxicity, abrogating stromal protection.